In vitro anti-hepatitis B virus effect of Hypericum perforatum L.

  • Ran Pang (庞 然)
  • Junyan Tao (陶君彦)
  • Shuling Zhang (张淑玲)
  • Jiang Zhu (朱 江)
  • Xin Yue (乐 鑫)
  • Lei Zhao (赵 雷)
  • Pian Ye (叶 翩)
  • Ying Zhu (朱 应)
Article

Summary

The anti-hepatitis B virus (HBV) effects and its mechanisms of the ethanol extracts of Hypericum perforatum L. (EHP) in vitro were explored. HepG2 2.2.15 cells, a stable HBV-producing cell line, were cultured as the model system to observe the anti-HBV effect. The viral antigens of cellular secretion, HBsAg and HBeAg, were determined by enzyme linked immunosorbent assay (ELISA). The quantity of HBV-DNA released in the supernatant was assayed by real-time PCR. In order to understand the mechanisms of the suppression of HBV replication, all HBV promoters (Cp, Xp, S1p, S2p and Fp) with luciferase reporter gene were transfected into HepG2 cells respectively. Then the activities of viral promoters were examined by luciferase reporter assay. It was found EHP effectively suppressed the secretion of HBsAg and HBeAg from HepG2 2.2.15 cells in a dose-dependent manner, as well as the extracellular HBV DNA. And EHP could selectively inhibit the activity of HBV promoter Fp. Our data suggest that EHP exerts anti-HBV effects via inhibition of HBV transcription, which helps to elucidate the mechanism underlying the potential therapeutic value of EHP.

Key words

hepatitis B virus Hypericum perforatum L. HBsAg HBeAg HBV DNA HBV promoter 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Savikin K, Dobric S, Tadic V, et al. Antiinflammatory activity of ethanol extracts of Hypericum perforatum L., H. barbatum Jacq., H. hirsutum L., H. richeri Vill. and H. androsaemum L. in rats. Phytother Res, 2007,21(2):176–180CrossRefPubMedGoogle Scholar
  2. 2.
    Roscetti G, Franzese O, Comandini A, et al. Cytotoxic activity of Hypericum perforatum L. on K562 erythroleukemic cells: differential effects between methanolic extract and hypericin. Phytother Res, 2004,18(1):66–72CrossRefPubMedGoogle Scholar
  3. 3.
    Jacobson JM, Feinman L, Liebes L, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John’s wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother, 2001,45(2):517–524CrossRefPubMedGoogle Scholar
  4. 4.
    Valentao P, Carvalho M, Fernandes E, et al. Protective activity of Hypericum androsaemum infusion against tert-butyl hydroperoxide-induced oxidative damage in isolated rat hepatocytes. J Ethnopharmacol, 2004,92(1):79–84CrossRefPubMedGoogle Scholar
  5. 5.
    Usai M, Leggio B, Grappi S, et al. Hypericum perforatum subspecies angustifolium shows a protective activity on the consequences of unavoidable stress exposure at lower doses than Hypericum perforatum perforatum. Pharmacopsychiatry, 2003, 36(6):283–287CrossRefPubMedGoogle Scholar
  6. 6.
    Ye P, Zhang SL, Zhao L, et al. Tea polyphenols exerts anti-hepatitis B virus effects in a stably HBV-transfected cell line. J Huazhong Univ Sci Technol Med Sci, 2009,29(2):169–172PubMedCrossRefGoogle Scholar
  7. 7.
    Moolla N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J Viral Hepat, 2002,9(5):323–331CrossRefPubMedGoogle Scholar
  8. 8.
    Choi BH, Park GT, Rho HM. Interaction of hepatitis B viral X protein and CCAAT/ enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter. J Biol Chem, 1999,274(5):2858–2865CrossRefPubMedGoogle Scholar
  9. 9.
    Park NH, Song IH, Chung YH. Chronic hepatitis B in hepatocarcinogenesis. Postgrad Med J, 2006,82(970):507–515CrossRefPubMedGoogle Scholar
  10. 10.
    Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat, 2002,9(6):393–399CrossRefPubMedGoogle Scholar
  11. 11.
    Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A, 1987,84(4):1005–1009CrossRefPubMedGoogle Scholar
  12. 12.
    Xu J, Wang J, Deng F, et al. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro. Antiviral Res, 2008,78(3):242–249PubMedGoogle Scholar
  13. 13.
    Li J, Huang H, Feng M, et al. In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L. Antiviral Res, 2008,79(2):114–120CrossRefPubMedGoogle Scholar
  14. 14.
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006,295(1):65–73CrossRefPubMedGoogle Scholar
  15. 15.
    Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 2006,130(3):678–686CrossRefPubMedGoogle Scholar
  16. 16.
    Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 2002,347(3):168–174CrossRefPubMedGoogle Scholar
  17. 17.
    Hoshida Y. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence. J Hepatol, 2009,51(5):842–844CrossRefPubMedGoogle Scholar
  18. 18.
    Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis, 2008,29(1):106–112CrossRefPubMedGoogle Scholar
  19. 19.
    McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology, 2009,49(5 Suppl):S45–S55PubMedCrossRefGoogle Scholar
  20. 20.
    Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol, 2006,101(8):1797–1803CrossRefPubMedGoogle Scholar
  21. 21.
    Tong Q, Wu Y, Luo D. Distribution of hepatitis B virus genotypes and its clinical significance in Hubei province, China. J Huazhong Univ Sci Technol Med Sci, 2007,27(3):274–277CrossRefPubMedGoogle Scholar
  22. 22.
    Howard CR. The structure of hepatitis B envelope and molecular variants of hepatitis B virus. J Viral Hepat, 1995,2(4):165–170CrossRefPubMedGoogle Scholar
  23. 23.
    Arbuthnot P, Carmona S, Ely A. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liver Int, 2005,25(1):9–15CrossRefPubMedGoogle Scholar
  24. 24.
    Shamay M, Barak O, Doitsh G, et al. Hepatitis B virus pX interacts with HBXAP, a PHD finger protein to coactivate transcription. J Biol Chem, 2002,277(12):9982–9988CrossRefPubMedGoogle Scholar
  25. 25.
    Tang H, Banks KE, Anderson AL, et al. Hepatitis B virus transcription and replication. Drug News Perspect, 2001,14(6):325–334PubMedGoogle Scholar
  26. 26.
    Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut, 2008,57(1):91–97CrossRefPubMedGoogle Scholar
  27. 27.
    Kwon JA, Rho HM. Hepatitis B viral core protein activates the hepatitis B viral enhancer II/pregenomic promoter through the nuclear factor kappaB binding site. Biochem Cell Biol, 2002,80(4):445–455CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer Berlin Heidelberg 2010

Authors and Affiliations

  • Ran Pang (庞 然)
    • 1
  • Junyan Tao (陶君彦)
    • 2
  • Shuling Zhang (张淑玲)
    • 1
  • Jiang Zhu (朱 江)
    • 3
  • Xin Yue (乐 鑫)
    • 4
  • Lei Zhao (赵 雷)
    • 1
  • Pian Ye (叶 翩)
    • 1
  • Ying Zhu (朱 应)
    • 4
  1. 1.Department of Hepatology and Infectious Disease, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.College of PharmacyHubei College of Traditional Chinese MedicineWuhanChina
  3. 3.Food Industry Research Institute of Jiangxi ProvinceNanchangChina
  4. 4.State Key Laboratory of Virology, College of Life SciencesWuhan UniversityWuhanChina

Personalised recommendations